Prior research supports the combination of PD-1 inhibitors with anti-CD30 antibodies in classical Hodgkin's lymphoma [28, 29], suggesting similar potential benefits for EBV + DLBCL. Here, TNFRSF8 is linked to Hodgkins lymphoma.